Wolverine Trading
LRMR icon

Wolverine Trading’s Larimar Therapeutics LRMR Stock Holding History

Wolverine Trading’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-978
Closed -$38K – 4836
2016
Q3 		$38K Buy
+978
New +$44.4K ﹤0.01% 4438

Other funds holding LRMR

GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wolverine Trading's LRMR Position: Q4 2016 in Review

Wolverine Trading sold out of Larimar Therapeutics (LRMR) in Q4 2016, closing a stake of 978 shares — an estimated $38K sold.

Wolverine Trading first reported a position in LRMR in Q3 2016 and held it in 1 quarter. The position peaked at $38K in Q3 2016. 81 funds tracked by Wall St. Rank hold LRMR as of Q4 2016.

  • Wolverine Trading reported no remaining Larimar Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Wolverine Trading sold 978 Larimar Therapeutics shares in Q4 2016, an estimated $38K.
  • Wolverine Trading first reported a position in Larimar Therapeutics in Q3 2016 and held it in 1 quarter.
  • Wolverine Trading's Larimar Therapeutics position peaked at $38K in Q3 2016.
  • 81 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2016.

Based on Wolverine Trading's 13F filing for Q4 2016, filed 14 Feb 2017.